Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 01, 2020 15:55 ET | Source: Intrommune Therapeutics

Media Alert: Interest in Peanut Allergy Market Heats up in the Wake of Aimmune/Nestlé Deal

NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- The recent $2.6 billion acquisition of Aimmune by Nestlé Health Science has helped shed light on the global peanut allergy problem. In January 2020,...
August 31, 2020 12:37 ET | Source: Bragar Eagel & Squire

AIMMUNE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AIMT and Encourages Investors to Contact the Firm

NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
September 16, 2019 14:25 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee Vote

New York, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...